BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-elevar-hengrui-fda-rivoceranib-camrelizumab-pdufa-july-2026@catalyst-calendar.local
DTSTAMP:20260601T102705Z
DTSTART:20260723T130000Z
DTEND:20260723T133000Z
SUMMARY:Elevar/Hengrui rivoceranib联合camrelizumab肝癌NDA/BLA PDUFA日期
DESCRIPTION:FDA已受理Elevar rivoceranib与恒瑞camrelizumab用于一线不可切除或转移性肝细胞癌的NDA/BLA重新提交，并设定2026-07-23为PDUFA目标日期。该事件是中国PD-1联合小分子VEGF路径在美国监管端的重要验证。\\nImpact score: 76\\nExpected: FDA决定将影响恒瑞创新药出海路径、PD-1/VEGF组合在HCC中的美国监管认可度以及中国创新药全球化风险溢价。\\nAffected: 600276.SH(licensee\, unknown\, score 84)\; HLB.KS(subject\, unknown\, score 80)\; 9926.HK(peer\, mixed\, score 55)\; XBI(etf\, mixed\, score 48)\\nSources: Elevar FDA acceptance release: https://elevartx.com/2026/02/02/elevar-fda-acceptance-rivo/\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-elevar-hengrui-fda-rivoceranib-camrelizumab-pdufa-july-2026
CATEGORIES:fda\,US\,FDA\,PDUFA\,HCC\,rivoceranib\,camrelizumab\,PD-1\,VEGF
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Elevar/Hengrui rivoceranib联合camrelizumab肝癌NDA/BLA PDUFA日期
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Elevar/Hengrui rivoceranib联合camrelizumab肝癌NDA/BLA PDUFA日期
END:VALARM
END:VEVENT
END:VCALENDAR